Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Jane Street Group LLC

Jane Street Group LLC cut its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 90.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,251 shares of the biopharmaceutical company's stock after selling 364,657 shares during the quarter. Jane Street Group LLC's holdings in Catalyst Pharmaceuticals were worth $777,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth $27,000. Farther Finance Advisors LLC increased its stake in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth $65,000. KBC Group NV increased its stake in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth $104,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CPRX has been the subject of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird raised their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Stephens restated an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $32.29.

Insider Buying and Selling

In related news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary Ingenito sold 44,000 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the sale, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,627,468.99. The trade was a 38.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 351,879 shares of company stock worth $8,214,815 over the last 90 days. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX traded up $0.04 during midday trading on Thursday, hitting $24.58. The company had a trading volume of 933,233 shares, compared to its average volume of 1,104,644. The company's 50-day simple moving average is $23.59 and its 200-day simple moving average is $22.59. The firm has a market capitalization of $3.00 billion, a P/E ratio of 20.83, a P/E/G ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.75 and a 1 year high of $26.16.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.